Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes

Authors:

Abstract
The Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication (DREAM) trial reported that 3 years of therapy with rosiglitazone reduced the primary outcome of diabetes or death by 60%. Here we investigated whether an effect on diabetes prevention persists more than 1.5 years after therapy has been discontinued.

This publication has 16 references indexed in Scilit: